Venetoclax
- Generic Name
- Venetoclax
- Brand Names
- Venclexta, Venclyxto
- Drug Type
- Small Molecule
- Chemical Formula
- C45H50ClN7O7S
- CAS Number
- 1257044-40-8
- Unique Ingredient Identifier
- N54AIC43PW
- Background
Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 . Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma . CLL is the most prevalent leukemia diagnosed in Western countries . Venetoclax was developed through reverse engineering of the BCL-2 protein family inhibitor, navitoclax . Venetoclax is approximately 10 times more potent than navitoclax with regard to induction of apoptosis in CLL cells . A new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy . Previously, this drug was indicated only for patients with 17p gene deletion .
- Indication
本品与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗，或者年龄75岁及以上的新诊断的成人急性髓系白血病患者。
- Associated Conditions
- Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Associated Therapies
- -
Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
- First Posted Date
- 2021-03-01
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 84
- Registration Number
- NCT04774393
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Interventions
- First Posted Date
- 2021-02-17
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- Paolo Ghia
- Target Recruit Count
- 55
- Registration Number
- NCT04758975
- Locations
- 🇮🇹
IRCCS Ospedale San Raffaele, Milano, MI, Italy
A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)
- Conditions
- Interventions
- First Posted Date
- 2021-02-16
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- ALX Oncology Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT04755244
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
🇺🇸Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
Clinical Study With Ibrutinib and Venetoclax for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2021-02-15
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Paolo Ghia
- Target Recruit Count
- 31
- Registration Number
- NCT04754035
- Locations
- 🇮🇹
Ospedale San Raffaele, Milano, MI, Italy
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
- Conditions
- Recurrent Chronic Myelomonocytic LeukemiaHematopoietic and Lymphoid Cell NeoplasmRecurrent Acute Myeloid LeukemiaRecurrent Acute Lymphoblastic LeukemiaRecurrent Myelodysplastic SyndromeRefractory Acute Lymphoblastic LeukemiaRefractory Acute Myeloid LeukemiaRefractory Chronic Myelomonocytic LeukemiaRefractory Myelodysplastic Syndrome
- Interventions
- First Posted Date
- 2021-02-12
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 17
- Registration Number
- NCT04752163
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy
- Conditions
- Interventions
- First Posted Date
- 2021-02-10
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- Celgene
- Target Recruit Count
- 1
- Registration Number
- NCT04748848
- Locations
- 🇺🇸
Local Institution - 121, New York, New York, United States
🇪🇸Local Institution - 802, Madrid, Spain
🇺🇸Local Institution - 104, Dallas, Texas, United States
Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT04746235
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
- First Posted Date
- 2021-02-05
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 55
- Registration Number
- NCT04739813
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-01-25
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 2
- Registration Number
- NCT04722601
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
- First Posted Date
- 2021-01-13
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 324
- Registration Number
- NCT04708054
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.